Skip to main content

Peripheral Arterial Occlusive Disease

3
Pipeline Programs
8
Companies
11
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Aplagon
AplagonFinland - Helsinki
2 programs
1
1
APAC - dose level 0.50 mg/kg,Phase 21 trial
[89Zr]Zr-DFO-APACPhase 11 trial
Active Trials
NCT06204237Recruiting10Est. Jun 2025
NCT07352800Recruiting42Est. Jun 2027
RHEACELL
RHEACELLGermany - Heidelberg
1 program
1
allo-APZ2-PAODPhase 1/21 trial
Active Trials
NCT03339973Terminated24Est. May 2020
Sanofi
SanofiPARIS, France
2 programs
XRP0038PHASE_11 trial
XRP0038PHASE_11 trial
Active Trials
NCT01157156Completed51Est. Sep 2001
NCT01157143Completed6Est. Oct 2003
Bracco
BraccoItaly - Milan
2 programs
VISIPAQUE 270PHASE_41 trial
iopamidolPHASE_41 trial
Active Trials
NCT00740207Completed33Est. Jul 2009
NCT01075217Completed174Est. Dec 2011
Abbott
AbbottABBOTT PARK, IL
1 program
PAD endovascular treatmentsN/A1 trial
Active Trials
NCT01855412Completed1,204Est. Apr 2019
B. Braun
B. BraunGermany - Melsungen
1 program
VascuFlex Multi-LOCN/A2 trials
Active Trials
NCT02900274Completed353Est. Dec 2020
NCT02531230Completed75Est. Aug 2017
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
AlprostadilPHASE_41 trial
Active Trials
NCT00596752Completed840Est. Jul 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Braccoiopamidol
BraccoVISIPAQUE 270
UCB PharmaAlprostadil
AplagonAPAC - dose level 0.50 mg/kg,
RHEACELLallo-APZ2-PAOD
Aplagon[89Zr]Zr-DFO-APAC
SanofiXRP0038
SanofiXRP0038
B. BraunVascuFlex Multi-LOC
B. BraunVascuFlex Multi-LOC
AbbottPAD endovascular treatments

Clinical Trials (11)

Total enrollment: 2,812 patients across 11 trials

NCT01075217Braccoiopamidol

Isovue in Peripheral Digital Subtraction Angiography (DSA)

Start: Apr 2010Est. completion: Dec 2011174 patients
Phase 4Completed
NCT00740207BraccoVISIPAQUE 270

Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA

Start: Sep 2008Est. completion: Jul 200933 patients
Phase 4Completed
NCT00596752UCB PharmaAlprostadil

Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV

Start: Mar 2004Est. completion: Jul 2013840 patients
Phase 4Completed
NCT07352800AplagonAPAC - dose level 0.50 mg/kg,

Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia

Start: Jan 2026Est. completion: Jun 202742 patients
Phase 2Recruiting
NCT03339973RHEACELLallo-APZ2-PAOD

Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD

Start: Mar 2018Est. completion: May 202024 patients
Phase 1/2Terminated
NCT06204237Aplagon[89Zr]Zr-DFO-APAC

Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)

Start: Feb 2024Est. completion: Jun 202510 patients
Phase 1Recruiting
NCT01157143SanofiXRP0038

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

Start: Jan 2002Est. completion: Oct 20036 patients
Phase 1Completed
NCT01157156SanofiXRP0038

Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

Start: Jun 1999Est. completion: Sep 200151 patients
Phase 1Completed
NCT02900274B. BraunVascuFlex Multi-LOC

"All Comers" Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes (LOCOMOTIVE Extended)

Start: Sep 2016Est. completion: Dec 2020353 patients
N/ACompleted
NCT02531230B. BraunVascuFlex Multi-LOC

"All Comers" Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes

Start: Jul 2015Est. completion: Aug 201775 patients
N/ACompleted
NCT01855412AbbottPAD endovascular treatments

Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes

Start: May 2013Est. completion: Apr 20191,204 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 2,812 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.